PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
15.23%
Net income growth under 50% of ZETA's 40.68%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
13.04%
Some D&A expansion while ZETA is negative at -1.61%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1200.00%
Working capital change of 1200.00% while ZETA is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
145.95%
Inventory growth of 145.95% while ZETA is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
No Data
No Data available this quarter, please select a different quarter.
2458.06%
Growth well above ZETA's 100.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
180.20%
Operating cash flow growth above 1.5x ZETA's 20.83%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
24.14%
CapEx growth well above ZETA's 14.14%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-44.86%
Negative yoy purchasing while ZETA stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
Both yoy lines negative, with ZETA at -39.54%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-24.83%
Both yoy lines negative, with ZETA at -18.84%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-23.47%
Negative yoy issuance while ZETA is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-165.89%
Both yoy lines negative, with ZETA at -23.83%. Martin Whitman would see an overall reduced environment for buybacks in the niche or cyclical factor driving capital usage.